CN101918423B - 二肽基肽酶-iv抑制剂 - Google Patents
二肽基肽酶-iv抑制剂 Download PDFInfo
- Publication number
- CN101918423B CN101918423B CN2008801181558A CN200880118155A CN101918423B CN 101918423 B CN101918423 B CN 101918423B CN 2008801181558 A CN2008801181558 A CN 2008801181558A CN 200880118155 A CN200880118155 A CN 200880118155A CN 101918423 B CN101918423 B CN 101918423B
- Authority
- CN
- China
- Prior art keywords
- compound
- dpp
- pharmaceutically acceptable
- acceptable acid
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 N#*[C@@](CCC1)N1C(CNC(CC1*2)(CC1(C1)C2C2)CC12O[C@@]([C@@]([C@](C1)O)O)O[C@@]1C(O)=O)O Chemical compound N#*[C@@](CCC1)N1C(CNC(CC1*2)(CC1(C1)C2C2)CC12O[C@@]([C@@]([C@](C1)O)O)O[C@@]1C(O)=O)O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
- B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
- B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
- B41J2/01—Ink jet
- B41J2/17—Ink jet characterised by ink handling
- B41J2/175—Ink supply systems ; Circuit parts therefor
- B41J2/17593—Supplying ink in a solid state
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US484607P | 2007-11-30 | 2007-11-30 | |
US61/004,846 | 2007-11-30 | ||
PCT/EP2008/066159 WO2009068531A2 (en) | 2007-11-30 | 2008-11-25 | Organic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101918423A CN101918423A (zh) | 2010-12-15 |
CN101918423B true CN101918423B (zh) | 2013-05-15 |
Family
ID=40679052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008801181558A Expired - Fee Related CN101918423B (zh) | 2007-11-30 | 2008-11-25 | 二肽基肽酶-iv抑制剂 |
Country Status (13)
Country | Link |
---|---|
US (2) | US8252751B2 (pt-PT) |
EP (1) | EP2247602B1 (pt-PT) |
JP (1) | JP5401465B2 (pt-PT) |
KR (1) | KR20100092461A (pt-PT) |
CN (1) | CN101918423B (pt-PT) |
AU (1) | AU2008328845C1 (pt-PT) |
CA (1) | CA2704493A1 (pt-PT) |
ES (1) | ES2418440T3 (pt-PT) |
MX (1) | MX2010005914A (pt-PT) |
PL (1) | PL2247602T3 (pt-PT) |
PT (1) | PT2247602E (pt-PT) |
RU (2) | RU2489439C2 (pt-PT) |
WO (1) | WO2009068531A2 (pt-PT) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011078101A1 (ja) | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | アダマンタンアミン誘導体 |
CN101798270B (zh) * | 2010-02-25 | 2013-04-17 | 东华大学 | 一种3-氨基-1-金刚烷醇的制备方法 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
US8901316B2 (en) | 2010-08-09 | 2014-12-02 | Shionogi & Co., Ltd. | Process for preparing aminoadamantyl carbamate derivatives |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
IN2012MU01383A (pt-PT) * | 2012-05-04 | 2014-02-28 | ||
JP5929555B2 (ja) * | 2012-06-28 | 2016-06-08 | 三菱瓦斯化学株式会社 | ヒドロキシアダマンタンカルボン酸化合物の製造方法 |
CN105142621A (zh) | 2012-10-24 | 2015-12-09 | 国家健康科学研究所 | 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂 |
CN103804267B (zh) * | 2014-02-21 | 2016-06-08 | 张家港威胜生物医药有限公司 | 一种维达列汀的合成工艺 |
CN105439873A (zh) * | 2014-08-20 | 2016-03-30 | 天津药物研究院 | 3-羟基-1-金刚烷胺的制备方法 |
ES2805743T3 (es) | 2015-03-24 | 2021-02-15 | Inst Nat Sante Rech Med | Método y composición farmacéutica para uso en el tratamiento de la diabetes |
CN104744334A (zh) * | 2015-03-25 | 2015-07-01 | 合肥创新医药技术有限公司 | 维格列汀的制备方法 |
CN107311907A (zh) * | 2017-07-29 | 2017-11-03 | 合肥创新医药技术有限公司 | 一种维格列汀异构体杂质的制备方法 |
CN111138334A (zh) * | 2020-01-13 | 2020-05-12 | 天津民祥生物医药股份有限公司 | 一种维格列汀的制备方法 |
JP7349475B2 (ja) | 2021-06-22 | 2023-09-22 | シャープ株式会社 | リレー制御回路および電源回路 |
WO2023233024A1 (en) * | 2022-06-03 | 2023-12-07 | Universiteit Antwerpen | Dpp9 binding compounds |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005012249A2 (en) * | 2003-08-01 | 2005-02-10 | Bristol-Myers Squibb Company | Adamantyglycine- based inhibitors of dipeptidyl peptidase iv for the treatment of diabetes |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
US6555519B2 (en) * | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
US7871982B2 (en) * | 2005-12-09 | 2011-01-18 | Meiji Seika Kaisha, Ltd. | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient |
-
2008
- 2008-11-25 CN CN2008801181558A patent/CN101918423B/zh not_active Expired - Fee Related
- 2008-11-25 RU RU2010126056/04A patent/RU2489439C2/ru not_active IP Right Cessation
- 2008-11-25 MX MX2010005914A patent/MX2010005914A/es active IP Right Grant
- 2008-11-25 CA CA2704493A patent/CA2704493A1/en not_active Abandoned
- 2008-11-25 AU AU2008328845A patent/AU2008328845C1/en not_active Ceased
- 2008-11-25 PT PT88533450T patent/PT2247602E/pt unknown
- 2008-11-25 JP JP2010535355A patent/JP5401465B2/ja not_active Expired - Fee Related
- 2008-11-25 WO PCT/EP2008/066159 patent/WO2009068531A2/en active Application Filing
- 2008-11-25 EP EP08853345A patent/EP2247602B1/en not_active Not-in-force
- 2008-11-25 PL PL08853345T patent/PL2247602T3/pl unknown
- 2008-11-25 US US12/744,510 patent/US8252751B2/en not_active Expired - Fee Related
- 2008-11-25 ES ES08853345T patent/ES2418440T3/es active Active
- 2008-11-25 KR KR1020107011725A patent/KR20100092461A/ko not_active Application Discontinuation
-
2012
- 2012-07-27 US US13/560,421 patent/US8569250B2/en not_active Expired - Fee Related
-
2013
- 2013-04-24 RU RU2013119129/04A patent/RU2013119129A/ru not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005012249A2 (en) * | 2003-08-01 | 2005-02-10 | Bristol-Myers Squibb Company | Adamantyglycine- based inhibitors of dipeptidyl peptidase iv for the treatment of diabetes |
Also Published As
Publication number | Publication date |
---|---|
MX2010005914A (es) | 2010-12-14 |
EP2247602A2 (en) | 2010-11-10 |
EP2247602B1 (en) | 2013-04-03 |
US8252751B2 (en) | 2012-08-28 |
WO2009068531A3 (en) | 2010-09-10 |
PL2247602T3 (pl) | 2013-08-30 |
RU2013119129A (ru) | 2014-10-27 |
RU2489439C2 (ru) | 2013-08-10 |
PT2247602E (pt) | 2013-07-10 |
US20120295860A1 (en) | 2012-11-22 |
US8569250B2 (en) | 2013-10-29 |
JP2011504903A (ja) | 2011-02-17 |
WO2009068531A2 (en) | 2009-06-04 |
AU2008328845C1 (en) | 2012-11-08 |
KR20100092461A (ko) | 2010-08-20 |
CN101918423A (zh) | 2010-12-15 |
AU2008328845B2 (en) | 2012-04-19 |
JP5401465B2 (ja) | 2014-01-29 |
RU2010126056A (ru) | 2012-01-10 |
US20100256080A1 (en) | 2010-10-07 |
CA2704493A1 (en) | 2009-06-04 |
AU2008328845A1 (en) | 2009-06-04 |
ES2418440T3 (es) | 2013-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101918423B (zh) | 二肽基肽酶-iv抑制剂 | |
CN1795193B (zh) | 用作过氧化物酶体增殖物激活受体的配体的n-酰基含氮杂环化合物 | |
CN100447139C (zh) | 苯磺酰氨基化合物和含有这些化合物的药物组合物 | |
CN101360743A (zh) | 作为ppar调节剂的多环的1,2,3,4-四氢-异喹啉衍生物和包含它们的组合物 | |
CN101356178A (zh) | 作为ppar调节剂的化合物和组合物 | |
CN101223164A (zh) | 作为肾素抑制剂的被取代的哌啶类 | |
CN101326180A (zh) | 哌嗪衍生物肾素抑制剂 | |
CN101304984A (zh) | 唑和噻唑ppar调节剂 | |
Arsenyan et al. | 8-Ethynylxanthines as promising antiproliferative agents, angiogenesis inhibitors, and calcium channel activity modulators | |
CN1980919A (zh) | 作为ppar调节剂的化合物和组合物 | |
CN101466668A (zh) | 作为肾素抑制剂的吡咯烷化合物 | |
CN101466707A (zh) | 用于对抗依赖于肾素活性的疾病的吡咯烷衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: NOVARTIS CO., LTD. Free format text: FORMER NAME: NOVARTIS AG |
|
CP01 | Change in the name or title of a patent holder |
Address after: Basel Patentee after: Novartis Ag Address before: Basel Patentee before: Novartis AG |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130515 Termination date: 20141125 |
|
EXPY | Termination of patent right or utility model |